Mage-b vaccine delivered by recombinant Listeria monocytogenes is highly effective against breast cancer metastases by Kim, S H et al.
Mage-b vaccine delivered by recombinant Listeria monocytogenes
is highly effective against breast cancer metastases
SH Kim
1, F Castro
1, D Gonzalez
1, PC Maciag
2,3, Y Paterson
3 and C Gravekamp*,1,4
1California Pacific Medical Center Research Institute, 475 Brannan Street, Ste 220, San Francisco, CA 94107, USA;
2Advaxis Inc., 675 US Highway 1,
North Brunswik, NJ 08902, USA;
3Department of Microbiology, University of Pennsylvania, 323 Johnson Pavilion, 36th St and Hamilton Walk,
Philadelphia, PA 19104-6076, USA
New therapies are needed that target breast cancer metastases. In previous studies, we have shown that vaccination with pcDNA3.1-
Mage-b DNA vaccine is effective against breast cancer metastases. In the study presented here, we have further enhanced the efficacy
of Mage-b vaccination through the improved delivery of the vaccine using recombinant Listeria monocytogenes (LM). Three
overlapping fragments of Mage-b as well as the complete protein-encoding region of Mage-b have been expressed as a fusion protein
with a truncated non-cytolytic form of listeriolysin O (LLO) in recombinant LM. These different Mage-b vaccine strains were
preventively tested for their efficacy against breast cancer metastases in a syngeneic mouse tumour model 4T1. The LM-LLO-Mage-
b/2nd, expressing position 311–660 of the cDNA of Mage-b, was the most effective vaccine strain against metastases in the 4T1
mouse breast tumour model. Vaccination with LM-LLO-Mage-b/2nd dramatically reduced the number of metastases by 96%
compared with the saline group and by 88% compared with the vector control group (LM-LLO), and this correlated with strong
Mage-b-specific CD8 T-cell responses in the spleen, after restimulation with Mage-b. However, no effect of LM-LLO-Mage-b/2nd was
observed on 4T1 primary tumours, which may be the result of a complete absence of Mage-b-specific immune responses in the
draining lymph nodes. Vaccination with LM-LLO-Mage-b/2nd could be an excellent follow-up after removal of the primary tumour, to
eliminate metastases and residual tumour cells.
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Breast cancer is the most common cancer among women around
the world (Althuis et al, 2005), and 40% of the women diagnosed
with breast cancer will progress to metastatic disease (Berkowitz
et al, 2000). Current treatment options for localised breast cancer
include surgical resection of the primary tumour, assessment of
the regional lymph nodes (LNs), and removal if positive, followed
by adjuvant chemotherapy or hormonal therapy (Scart et al, 2002).
Although first-line endocrine therapy with tamoxifen or the newer
third generation aromatases is promising (Kurtz and Dufour,
2002), the cure rate of metastatic breast cancer is low (Alberg and
Singh, 2001). Despite aggressive treatment, for most patients the
elimination of metastases or residual tumour cells after surgery is
incomplete, due to chemoresistance (Pardal et al, 2003). Thus,
metastases and not the primary tumour is the most important
contributor to breast cancer morbidity and mortality. Treatments
that specifically reduce or eliminate distant metastases or residual
tumour cells should therefore be the focus of our efforts, and will
offer the greatest promise in improving the outcome for patients
with metastatic breast cancer. Enhancement of specific helper and
cytotoxic T-lymphocyte (CTL) responses to breast tumours
through vaccination with tumour-associated antigens (TAAs)
could potentially lead to the specific elimination of micro-
metastases and/or residual tumour cells.
So far, many TAA have been identified in human tumours of
various histological origins. The MAGE antigens are particularly
interesting for the development of breast cancer vaccines, because
their expression (MAGE-A and/or MAGE-B) has been frequently
detected in human breast tumour biopsies (92%) (Park et al, 2002),
but not in normal tissues (De Backer et al, 1995; De Plaen et al,
1999). Various clinical trials have shown that vaccination with
MAGE-1 and -3 peptides or protein, in patients with melanoma was
effective against metastases (Thurner et al, 1999; Marchand et al,
2003; Kruit et al, 2005; Lurquin et al, 2005; Van Baren et al, 2005).
These human clinical trials not only show the potential of MAGE
vaccination against metastases but also the need to further optimise
the efficacy of MAGE-based vaccines to improve the clinical
outcome. Such optimisations are ideally carried out in the mouse.
In previous studies, we demonstrated that DNA vaccination with
mouse Mage-b in metastatic mouse breast tumour models 4TO7cg
and 4T1, highly expressing Mage-b, reduced the number of
metastases significantly, although not completely (Sypniewska
et al, 2005; Gravekamp, 2007; Gravekamp et al, 2008). In the study
presented here, we further enhanced the efficacy of Mage-b vaccine
through improved delivery of the vaccine using recombinant
Listeria monocytogenes (LM). Listeria monocytogenes is an
intracellular pathogen that primarily infects antigen-presenting
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scells (APCs) such as macrophages and dendritic cells (DCs; for
review see Paterson and Maciag, 2005). Listeria monocytogenes is
an attractive vaccine vector, because proteins produced by this
bacterium can be presented as short peptides through both the
MHC class I and II pathways generating both CD4 and CD8 T-cell
responses to these antigens (Hsieh et al, 1993). Direct killing of
tumour cells occurs through the function of CD8 T cells, but the
killing may be enhanced through the activation of CD4 T cells
(Hsieh et al, 1993). It has been shown that vaccine antigens
delivered through LM are effective against primary tumours in
animal models (Pan et al, 1999; Gunn et al, 2001; Singh et al, 2005).
As discussed earlier, metastases, and not the primary tumour,
contributes most to breast cancer morbidity and mortality. In this
study, we demonstrate a dramatic effect of Mage-b vaccination
delivered through LM on metastases in a highly metastatic breast
tumour model 4T1.
MATERIALS AND METHODS
Mice
Normal female Balb/c mice (3-month old) were obtained from
Simsonsen (San Francisco, CA, USA) and maintained in the animal
husbandry facility of the Pacific Medical Center Research Institute
(CPMCRI) according to the Association and Accreditation of
Laboratory Animal Care (AACAC) guidelines.
Plasmids and Listeria monocytogenes
pcDNA3.1-Mage-b/V5 was developed in our laboratory (Sypniewska
et al, 2005). Mouse GM-CSF plasmid (CMV1-GM-CSF) was kindly
provided by Dr Stephen Johnston (the Center for Innovations in
Medicine, the Biodesign Institute at Arizona State University)
(Chambers and Johnston, 2003). The listerial pGG-34 plasmid,
expressing the positive regulatory factor A (prfA), was developed in
the laboratory of Yvonne Paterson, University of Pennsylvania, PA,
USA (Singh et al, 2005). The prfA-negative strain XFL-7 of LM
(Gunn et al, 2001) has been used in this study.
Cells and cell culture
The 4T1 cell line was derived from a spontaneous mammary
carcinoma in a BALB/c mouse (Aslakson and Miller, 1992).
Various 4T1 sublines have been generated with different patterns
of metastases (Lelekakis et al, 1999). The 4T1 cell line used in this
study is highly aggressive, metastasizing predominantly to the
mesenteric LNs (MLNs), and less frequently to the diaphragm,
portal liver, spleen, and kidneys (Gravekamp et al, 2008). The 64pT
mouse mammary tumour cell line is a spontaneous fusion between
mammary cell lines 4TO7 and 68H and is non-metastatic (Rak
et al, 1992). Both 4T1 and 64pT were kindly provided by Dr Fred
Miller (Karmanos Cancer Institute, Detroit, MI, USA). Both cell
lines were grown in Dulbecco’s Modified Eagle’s Medium (DMEM)
supplemented with 10% foetal bovine serum (FBS), 1mM mixed
non-essential amino acids, 2mML -glutamine, insulin (0.5 HSP
units per ml) penicillin (100Uml
 1) and streptomycin
(100mgml
 1)
Breast tumours and metastases
Breast tumours and metastases were generated in BALB/c mice by
the injection of 10
5 cells of the mouse mammary tumour cell line
4T1, into a mammary fat pad as described previously (Gravekamp
et al, 2008). Primary tumours were detected by palpation within
1–2 weeks in live mice. To determine the tumour size in situ, the
perpendicular largest diameters of the tumour were measured with
a caliper. Fourteen days after injection of the tumour cell line, the
mice were euthanized, weighed, and necropsied to evaluate the
presence and frequency of metastases and to determine the weight
and size of primary tumours. Primary tumours extended to the
chest cavity lining, and predominantly metastasized to the MLNs
(81%), and less frequently to the diaphragm (7%) and portal liver
(4%), as well as to the surface of spleen (4%) and kidneys (4%).
Metastases were visible to the naked eye as nodules. The total
number of metastases per mouse (MLN, diaphragm, liver, kidney,
and spleen) was determined. Normal and tumour tissues were
collected aseptically and kept at  801C, or fixed in 10% Zinc
solution for 48h and kept in 70% ethanol, until use. The primary
tumours and metastases were confirmed by histology or RT–PCR.
In some cases, the metastases were too small for histological
analysis, and only RT–PCR for the detection of Mage-b expression
(not expressed in normal cells) was performed. Normal cells do
not express Mage-b.
Construction and characterisation of LM-based Mage-b
vaccine strains
Three overlapping fragments as well as the complete protein-
encoding region of Mage-b were cloned in the prfA-positive
plasmid pGG-34 (Gunn et al, 2001) under the control of a
hemolysin promoter (Phly), and as fusion protein with a truncated
non-cytolytic form of listeriolysin O (LLO). The first fragment
located at the N-terminal site is 349bp (position 3–352), the
second fragment adjacent to the first fragment is also 349bp
(position 311–660), and the third fragment at the C-terminal site is
379bp (position 610–990). The Mage-b fragments were obtained
by PCR from plasmid pcDNA3.1-Mage-b/V5, generated in a
previous study (Sypniewska et al, 2005). For each construct, a
restriction site Xho1 (underlined) was included in the forward
primer, and a myc Tag (bold), followed by a stop codon and
restriction site XmaI (underlined) in the reverse primer. The
following primers were designed to generate the first fragmant
of Mage-b F
1st/50: CTCGAGCCTAGGGGTCAAAAGAGTAAG and
R
1st/50:CCCGGGTTATAGATCTTCTTCTGAAATTAGTTTTTGTTCA
AACTTATCTAGCAGGAATTC; for the second fragment of
Mage-b F
2nd/50: CTCGAGAGGAAGGCTA GTGTGCTGATA and
R2nd/50: CCCGGGTTATAGATCTTCTTCTG AAATTAGTTTTTGTT
CTCCATGCAGAAATTGCCAGAC were designed; and for the third
fragment of Mage-b F
3rd/50: CTCGAGAACCGTGCCACTGAGCAAG
AG and R
3rd/50: CCCGGGTTATAGATCTTCTTCTGAAATTAGT
TTTTGTTCCATGTTAGAGGACTTTTGGGA were designed. The
Mage-b fragments or complete Mage-b were cloned into the listerial
pGG-34 plasmid by digestion of the PCR products of Mage-b as well
as the pGG-34 plasmid with XHoI and SmaI, followed
by purification of the digests and ligation of pGG-34 with Mage
using T4 DNA polymerase (Invitrogen, Life Technologies) and
transformed into Escherichia coli. Positive colonies were analysed
by restriction digestion with XHoI and SmaI, and DNA sequencing.
Subsequently, the plasmids of positive colonies were transformed
into the recombinant prFA-negative LM strain XFL-7 (Hsieh et al,
1993) and analysed for the secretion of the Mage proteins
by western blotting as described below. The LM-LLO used in
this study is attenuated, that is, the coding region for the
C-terminal part of the LLO (cytolytic domain that binds
cholesterol in the membranes) protein has been deleted, and
mutations have been introduced into the prfA gene (expressed by
the pGG34 vector), which reduced the pathogenicity of the LM
(Singh et al, 2005).
Western blotting
The Mage-b LM-based vaccines were grown overnight in Luria–
Bertani medium with 50mgml
 1 of chloroamphenicol at 371C.
Supernatants were precipitated with trichloro acetic acid (TCA)
and resuspended in SDS sample buffer (Invitrogen, Life Techno-
logies). Twenty microliters of each sample was loaded on a 4–12%
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sBis-Tris SDS–PAGE gel (Invitrogen, Life Technologies). The
proteins were then transferred to a nitrocellulose membrane and
probed with a rabbit polyclonal antiserum raised to the first 30
residues of the LLO protein (anti-proline, glutamic acid, serine,
and threonine (PEST) (Pan et al, 1999). The secondary antibody
(Ab) was an HRP-conjugated anti-rabbit Ab (Pharmingen). In
addition, transferred proteins were probed with mouse anti-myc
Abs, followed by a goat antimouse IgG conjugated with HRP as
secondary Ab.
RT–PCR and southern blotting
RNA was isolated using Trizol according to the manufacturer’s
instructions (Life Technologies, Carlsbad, CA, USA). Conversion
of 1mg of mRNA into cDNA was performed with Superscript
Preamplification system (Life Technologies). Subsequently, 10mlo f
the cDNA was amplified by hot start PCR (Platinum PCR
SuperMix, Life Technologies; 40 cycles at 941C for 30s, 581C for
30s, 721C for 2min) in a thermocycler from Perkin-Elmer
(Norwalk, CT, USA). To detect the expression of all three genes,
that is, Mage-b1, -b2,o r-b3, we used the set of primers F111 50-G
AGCTTGATCCACGAGTTC-30 and R769: 50-AGGAGACCTGTCC
TAGGC-30 published by De Backer et al (1995). The forward
primer is located in the second exon and the reverse primer in the
third exon of Mage-b2, amplifying a 658bp fragment. b-actin was
used as an internal control for RNA quality. Primers for b-actin
were 50-TCATGAAGTGTGACGTTGACATCCGT-30, and 50-CCTA
GAAGCATTTGCGGTGCACGATG-30 (Life Technologies). RT–
PCR products were separated in an ethidium–bromide-stained
agarose gel, and transferred to an immobilon-N
þ membrane
(Amersham, Buckinghamshire, England) and hybridised with a
chemiluminescence-labelled and sequenced 993bp Mage-specific
probe (AY196960) according to the manufacturer’s instructions
(enhanced chemiluminescence; Amersham).
Immunisation and tumour challenge
The LD50 of each Mage-b vaccine strain was determined by
vaccinating five mice with various doses of each vaccine strain
(10
5,1 0
6,1 0
7,1 0
8 colony-forming units (CFU)) in 500ml saline. The
LD50 for all constructs was 10
8 CFU.
To determine the efficacy of each Mage-b vaccine strain, Balb/C
mice were immunised intraperitoneally (three times; 1 week time
interval) with 0.1 LD50 of each construct separately or combined
(LM-LLO-Mage-b/1st, LM-LLO-Mage-b/2nd, LM-LLO-Mage-b/3d,
LM-LLO-Mage-b/complete), or with 0.1 LD50 of the control
vector (LM-LLO), or with saline. For tumour induction, mice
were injected with 10
5 4T1 tumour cells into a mammary fat
pad 4 days after the second immunisation. Fourteen days after
tumour challenge, the mice were euthanized and analysed for
tumour size, frequency, and location of metastases. A schematic
view of the immunisations and tumour challenge is given in
Figure 1.
In vitro analysis of Mage-b-specific immune responses
Cells from draining (inguinal) LNs and spleens were isolated
according to standard protocols (Reeves and Reeves, 2003) from
BALB/c mice with or without 4T1 tumours, that were immunised
three times with 0.1 LD50 of the vaccine (LM-LLO-Mage-b/2nd),
or with 0.1 LD50 the control vector (LM-LLO), or saline. Within
each group, the spleen cells were pooled. Briefly, 2 10
5 cells from
spleens or LNs were restimulated with 5 10
4 bone marrow (BM)
cells (transfected with pcDNA3.1-Mage-b plasmid DNA and
pCMV-GM-CSF plasmid DNA (1mg of each plasmid DNA per
5 10
6 BM cells), using the Nucleofector kit of AMAXA
(Gaithersburg, MD, USA), and cultured in 200ml of RPMI
containing 10% FBS. Two days later, the frequency of IFNg- and
interleukin (IL)-2-producing cells was determined by ELISPOT
according to the standard protocols (Pharmingen, San Diego, CA,
USA). Positive cells were counted by an ELISPOT reader (CTL
Immunospot S4 analyzer, Cellular Technology Ltd, Cleveland, OH,
USA). Spleen cells were depleted for CD8 T cells, using magnetic
bead depletion techniques according to the manufacturer’s
instructions (Miltenyi Biotec Inc., Auburn, CA, USA). Fluores-
cence-activated cell sorting analysis showed that X90% of all CD8
T cells were removed after depletion (data not shown).
The effect of IL-6 on Mage-b-specific immune responses
To test the effect of IL-6 on Mage-b-specific immune responses
in vitro, purified IL-6 (100pgml
 1) was added or not to the wells
with spleen cells (2 10
5) and BM cells expressing Mage-b
(5 10
4) in 200ml of RPMI containing 10% FBS. Two days later,
the number of IFNg-producing cells was determined by ELISPOT
reader as described above. In addition, anti-IL-6 antibodies
(50mgml
 1) were either or not added to the wells with LNs
(2 10
5) and syngeneic 64pT tumour cells (1 10
4; treated with
mitomycin C; expressing highly Mage-b; Gravekamp et al, 2004),
and secreting highly IL-6 (3000pgml
 1) (Gravekamp et al, 2008),
in 200ml of RPMI containing 10% FBS. Two days later, the
production of IFNg was determined by quantitative ELISA as
described previously (Sypniewska et al, 2005). Anti-IL-6 antibodies
and purified IL-6 were purchased from Pharmingen.
RESULTS
Generation of the LM strains that secrete Mage-b
Three recombinant LM strains that express and secrete over-
lapping fragments of Mage-b, as well as the complete protein-
encoding region of Mage-b have been designed and constructed
(Figure 2A). These fragments of Mage-b were selected as
alternative antigens for the following reasons: (1) to lose function
of Mage-b (complete Mage-b may induce the growth of
tumour cells (Yang et al, 2007), (2) smaller fragments are easier
to secrete than larger fragments, and (3) to select the fragment with
the most protective effect in vivo. All fragments have been
cloned into the listerial pGG-34 expression vector as fusion
protein with LLO. Listeriolysin O was used for its ability to
improve the immunogenicity of poor immunogenic self-antigens
(Singh et al, 2005). The secretion of Mage-b protein of each
fragment, as well as the complete protein-encoding region of
Mage-b has been confirmed by western blotting of the secreted
listerial proteins (Figure 2B). The secreted fusion proteins
LM-LLO/Mage-b/1st, 2nd, and 3rd are 61kDa, whereas the
1st 2nd 3rd
Tumour
challenge termination
1w 2w
2w
Immunisation
0
Figure 1 Schematic view of immunisations and tumour challenge.
BALB/c mice were immunised three times intraperitoneally with 0.1 LD50
of each Listeria-based Mage-b vaccine strain or with the vector control
strain LM-LLO, or saline, with 1-week time intervals. Four days after the
second immunization, mice were injected with 10
5 4T1 tumour cells in a
mammary fat pad. Two weeks after tumour challenge, mice were
euthanized and analysed.
Vaccine therapy against breast cancer metastases
SH Kim et al
743
British Journal of Cancer (2008) 99(5), 741–749 & 2008 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sLM-LLO-Mage-b/complete is 88kDA. It is clear from Figure 2B
that the Mage-b fragments were more efficiently secreted than the
complete Mage-b.
Mage-b transcripts in 4T1 primary tumours and
metastases
To confirm the expression of Mage-b in the 4T1 primary tumours
and metastases (MLNs, diaphragm, portal liver, spleen, and
kidneys), we randomly analysed tissue samples from primary
tumours and metastases by RT–PCR and southern blotting
(Figure 3). All primary tumours and metastases, except
two metastases present on the surface of the spleen, did express
Mage-b. From one metastasis, the quality of the mRNA was poor,
as indicated by the absence of b-actin transcription products.
The other metastasis may have lost Mage-b expression.
Preventive effect of vaccination with the various LM-based
Mage-b vaccine strains
The preventive effect of each LM-based Mage-b vaccine strain
on metastases and primary tumours has been determined in
the 4T1 model. Mice were immunised with the vaccine strains
and challenged with 4T1 tumour cells as outlined in Figure 1. It
appeared that LM-LLO-Mage-b/2nd was the most effective vaccine
strain (Figure 4A). LM-LLO-Mage-b/2nd vaccination significantly
reduced the number of metastases by 96% compared with the
saline group and by 92% compared with the vector control group
(LM-LLO). The average number of metastases as determined for
each group was 9 (LM-LLO-Mage-b/2nd), 104 (LM-LLO), and 199
(saline). However, none of the Mage-b vaccine strains reduced the
growth of the primary tumours (Figure 4B). Moreover, the LM
strain expressing the complete Mage-b enhanced the tumour
growth by more than two times compared with the saline group
(Mann—Whitney, P¼0.0005). Therefore, LM-LLO-Mage-b com-
plete was excluded from further vaccine studies. In previous
studies, we have shown that complete Mage-b is able to enhance
tumour growth (Yang et al, 2007). Our results suggest that LM-
LLO-Mage-b may have a direct effect on the tumour cells. This idea
is currently under investigation.
In summary, LM-LLO-Mage-b/2nd was the most effective strain
and therefore selected for further analysis. Vaccine studies with
LM-LLO-Mage-b/2nd were repeated to confirm its dramatic effect
on the metastases, and to analyse Mage-b-specific immune
responses in vitro.
Vaccinations with LM-LLO-Mage-b/2nd were repeated three
times in the 4T1 model. Immunization with LM-LLO-Mage-b/2nd
significantly reduced the number of metastases by 96% compared
with the saline group and by 88% compared with the vector
control group (LM-LLO; Figure 4C). The average number of
metastases per group as determined was 7 (LM-LLO-Mage-b/2nd),
59 (LM-LLO), and 158 (saline). Again, while the effect was
dramatic on the metastases, no effect of LM-LLO-Mage-b/2nd was
observed on the primary tumour (Figure 4D).
Pure preventive immunizations, that is, three immunisations
followed by tumour challenge, 10 days after the last immunisation,
resulted also in a significant reduction in the number of metastases
in the mice immunised with LM-LLO-Mage-b/2nd compared with
the saline group (Mann—Whitney, P¼0.0159) but not compared
with the control vector group (data not shown). Moreover, two
immunisations before and one after tumour challenge were more
effective than three preventive immunisations.
Mage-b
-actin 285 bp
658 bp
12 3 4 5 6 7 89 1 01 11 21 3
Figure 3 Expression of Mage-b in 4T1 primary tumours and metastases.
The Mage-b-specific RT–PCR product of 632bp was detected by southern
blotting using DNA probe encoding Mage-b. b-actin (285bp) was used to
determine RNA quality. The lanes were loaded as follows: lane 1: normal
breast tissue; lane 2: 4T1 tumour; lane 3: 4T1 tumour; lane 4: metastasis in
peritoneal cavity (PC); lane 5: metastasis in PC; lane 6: metastasis liver; lane
7: metastasis liver; lane 8: metastasis spleen; lane 9: metastasis spleen; lane
10: metastasis kidney; lane 11: metastasis kidney; lane 12: metastasis
diaphragm; lane 13: metastasis diaphragm.
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Figure 2 Construction and characterisation of Listeria-based Mage-b
vaccine strains. (A) Three overlapping fragments of mouse Mage-b
(homologous to human MAGE-B) were cloned as a fusion protein with a
truncated non-cytolytic listeriolysin O (LLO) in the pGG-34 vector under
the control of the listerial hemolysin promoter (Phly). (B) Secretion of
LLO-Mage-b proteins by the Listeria-based vaccine strains was detected by
western blotting using a-myc antibodies (top) and a-pest antibodies
(bottom). In the western blot with a-myc antibodies, the LLO-Mage-b
proteins are indicated by black arrows, and in the western blot with a-pest
antibodies by white arrows. The complete Mage-b protein fused with
truncated LLO represents a band of 88kDa, whereas the three fragments
of Mage-b fused with truncated LLO represent a band of 61kDa.
Endogenous LLO (58KDa) secreted by all LM is indicated by a star.
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sMage-b-specific immune responses in vitro
Mage-b-specific immune responses were analysed in spleen and
LNs of vaccinated and control mice. First, vaccinated and control
mice without 4T1 tumours and metastases were analysed for Mage-
b-specific immune responses. A significant increase was observed
in the number of IFNg-producing cells in the group of LM-LLO-
Mage-b/2nd compared with the control groups, demonstrating the
high immunogenicity of Mage-b/2nd (Figure 5A). Second,
vaccinated and control mice bearing 4T1 tumours and metastases
were analysed for Mage-b-specific immune responses. A signifi-
cant increase in the number of IFNg-producing cells was observed
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Figure 4 Strong effect of vaccination with LM-LLO-Mage-b/2nd on metastases but not on primary tumours in the 4T1 model. BALB/c mice were
immunised with the various Listeria-based Mage-b vaccine strains and challenged with 4T1 tumour cells as outlined in Figure 1. Two weeks after tumour
challenge, mice were euthanized and the number of metastases (A) and tumour size (B) was determined per mouse. LM-LLO-Mage-b/2nd was the most
effective vaccine strain against 4T1 metastases, whereas none of the Listeria-based Mage-b vaccines had any inhibitory effect on tumour growth. These
vaccine studies were repeated three times in independent experiments with the most effective vaccine strain, that is, the LM-LLO-Mage-b/2nd. Again, the
number of metastases (C) and tumour size (D) was determined per mouse. Results were averaged and subjected to statistical analysis using Mann–Whitney
test (n¼5 mice per group in each experiment). The error bars represent the s.e.m. In panel C, each triangle represents the number of metastases per
mouse, and the vertical bars represent the average number of metastases per mouse.
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sin the group of LM-LLO-Mage-b/2nd compared with the control
groups (Figure 5B), demonstrating that LM-LLO-Mage-b/2nd was
able to induce Mage-b-specific immune responses even in mice
with 4T1 tumours. Finally, immune responses in the spleens were
compared with immune responses in the draining LNs (at the site
of the primary tumours), both isolated from the same mice with
4T1 tumours and metastases, and restimulated in the same
experiment, as described above. While strong Mage-b-specific
immune responses were observed in the spleen (Figure 5C), those
immune responses were completely absent in the draining LNs
(Figure 5D). Depletion of CD8 T cells showed a decrease in the
number of IFNg-producing cells in the spleen by 80% (Figure 5C).
No significant increase was observed in the number of IL-2-
producing cells of the group of vaccinated mice compared with the
control mice and therefore not shown.
The effect of IL-6 on Mage-b-specific immune responses
in vitro
As shown in Figure 5C and D, Mage-b-specific CD8 T-cell
responses were present in the spleen, but completely absent at
the site of the primary tumours (in draining LN). This implies that
at the site of the primary tumours, either Mage-b-specific CD8 T
cells are absent, or that Mage-b-specific CD8 T cells are present but
failed to function, for example, by the factor(s) produced by the
primary tumours. We analysed this latter possibility. In previous
studies, we found that 4T1 primary tumours produced high levels
of IL-6 (Gravekamp et al, 2008). Interleukin-6 is a potential
candidate for T-cell inhibition. In the current study, the effect of
anti-IL-6 antibodies as well as of purified IL-6 on Mage-b-induced
immune responses has been analysed in vitro. For this purpose,
anti-IL-6 antibodies were added to LNs of 4T1 tumour-bearing
mice, restimulated with Mage-b. To avoid the generation of
immune responses against all other TAA than Mage-b, we used
64pT instead 4T1 tumour cells in the restimulation assay. 64pT
is a syngeneic breast tumour cell, highly expressing Mage-b
(Gravekamp et al, 2004) and highly secreting IL-6 (3000pgml
 1)
(Gravekamp et al, 2008). Indeed, addition of anti-IL-6 antibodies
to the in vitro restimulation assay significantly increased the
production of IFNg, whereas the production of IFNg could not be
induced in the same restimulation assay without anti-IL-6
antibodies (Figure 6A). In accordance with this result, the addition
of purified IL-6 to spleen cells of 4T1 tumour-bearing mice that
were immunised with LM-LLO-Mage-b/2nd, completely inhibited
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Figure 5 Mage-b-specific immune responses in vitro. BALB/c mice were immunised with the LM-LLO-Mage-b/2nd vaccine strain and challenged with 4T1
tumour cells as outlined in Figure 1, or not challenged with 4T1 tumour cells. Two weeks after tumour challenge, mice were euthanized and spleens and
draining (inguinal) lymph nodes (LNs) were analysed for in vitro immune responses upon restimulation with Mage-b. For this purpose, the number of IFNg-
producing cells in spleens of mice without (A) and with (B) 4T1 tumours and metastases were compared. Again, the number of IFNg-producing cells were
determined in spleens (C) but now compared with the number of IFNg-producing cells in the LNs (D) of mice bearing 4T1 tumours and metastases were
compared. Lymph nodes and spleens were from the same mice, and tested in the same experiment. In panel C, spleen cells depleted for CD8 T cells are
shown as well. All restimulation assays were performed with bone marrow (BM) cells transfected with pcDNA3.1-Mage-b and pCMV1-GM-CSF plasmid
DNA. Two days later, Mage-b-specific immune responses were analysed by ELISPOT. Controls such as BM cells transfected with pcDNA3.1-Mage-b, or
with pCMV-GM-CSF, or non-transfected BM cells did not produce IFN (data not shown). The LM-LLO-Mage-b/2nd vaccine was tested in three
independent experiments. Results were averaged and subjected to statistical analysis using Mann–Whitney test (n¼5 mice per group in each experiment).
The error bars represent the s.e.m.
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sthe generation of IFNg-producing cells upon restimulation with
BM cells highly expressing Mage-b, while in the absence of purified
IL-6, a high number of IFNg-producing cells was detected
(Figure 6B).
DISCUSSION
Clinical trials have shown that vaccination with MAGE has effect
on metastases (Thurner et al, 1999; Marchand et al, 2003; Kruit
et al, 2005; Lurquin et al, 2005; Van Baren et al, 2005), but
improvement of MAGE vaccines is strongly needed. In previous
studies, we have shown that immunisation with Mage-b combined
with GM-CSF plasmid DNA and thioglycollate reduced the number
of metastases by 65% compared with the control group in a highly
metastatic breast tumour model, 4T1 (Gravekamp et al, 2008). In
this study, we have further improved Mage-b vaccination by using
an improved delivery system, that is, recombinant LM. Listeria
monocytogenes infects primarily APC such as macrophages and
DCs, and delivers the Mage-b antigen with high efficiency to the
APC. Three overlapping fragments of Mage-b (LM-LLO-Mage-b/
1st, LM-LLO-Mage-b/2nd, and LM-LLO-Mage-b/3rd) as well as the
complete protein-encoding region of Mage-b (LM-LLO-Mage-b/
complete) have been expressed in recombinant LM. Each fragment
of Mage-b as well as the complete Mage-b is secreted as a fusion
protein with a truncated, non-cytolytic form of LLO. Most effective
was the LM-LLO-Mage-b/2nd vaccine strain. Vaccination with LM-
LLO-Mage-b/2nd dramatically reduced the number of metastases
by 96% compared with the saline group and by 88% compared
with the vector control group, and this correlated with strong
Mage-b-specific CD8 T-cell responses in the spleen upon
restimulation with Mage-b. These results suggest that LM-LLO-
Mage-b/2nd (position 311–660 of the cDNA of Mage-b) may
contain a higher number of, or more effective protective epitope(s)
than LM-LLO-Mage-b/1st or LM-LLO-Mage-b/3rd. No further
analysis has been performed in this study to identify protective
epitope(s) within the Mage-b protein. We have studied Mage-b-
specific CD8 T cells secreting IFNg, as tumour cell kill is mediated
through CD8 function (Singh et al, 2005). However, recent studies
show that CD4 helper T cells, secreting IFNg, may play an
important role in tumour rejection as well (Qian et al, 2004;
Chikamatsu et al, 2008).
The LM-LLO had an effect on the metastases, and it significantly
reduced the number of metastases compared with the saline group.
Evidence exists that LM-LLO itself can activate CD8 T cells, as well
as NK cells and NK DCs (NKDCs) to produce IFNg in vivo
(Messingham et al, 2007; Plitas et al, 2007). Indeed, we found IFNg-
producing CD8 T cells, NK cells, and macrophages, in spleen
cultures of mice immunised with LM-LLO or LM-LLO-Mage-b/
2nd, restimulated with LM-LLO (data not shown). IFNg has an
antimetastatic effect (Hayakawa et al, 2002), and may explain the
effect of LM-LLO on the metastases.
Despite the dramatic effect on the metastases, no reduction in
the growth of 4T1 primary tumours was observed in mice
vaccinated with the LM-LLO-Mage-b/2nd or with the other Mage
vaccine strains compared with the control groups. In correlation
with this effect, we found that Mage-b-specific immune responses
were completely absent in the LNs at the site of the primary
tumours. However, both 4T1 tumours and metastases expressed
high levels of Mage-b. This implies that Mage-b-specific CD8 T
cells are either absent, or present but inhibited in function at the
site of the primary tumours. In previous studies with pcDNA3.1-
Mage-b vaccination, we found that the number of CD8 T cells
significantly increased in the 4T1 tumours of Mage-b vaccinated
mice compared with the control groups, despite very poor Mage-b-
specific immune responses (IFNg production) in the draining LNs
(Gravekamp et al, 2008). With this in mind, the inhibition of T-cell
function may be more likely than the absence of Mage-b-specific
CD8 T cells at the site of the primary tumours. Many tumours
produce and accumulate lymphokines or factors at high levels that
may inhibit vaccine-induced T-cell responses such as IL-6,
transforming growth factor (TGFb), IL-10, cyclooxygenase
(COX)-2, and its product prostaglandine E, PD1-ligand or
indolamine, 2,3-dioxygenase (IDO; Gajewski et al, 2006). In a
previous study, we found that IL-6 and TGFb are highly produced
by the 4T1 primary tumours and metastases (Gravekamp et al,
2008). Evidence exists that TGFb may induce regulatory T cells
(Tregs) (DiPaolo et al, 2007) at the site of the primary tumour.
Indeed, very recently, it has been reported that 4T1 tumours are
massively infiltrated with Tregs preventing efficient activation
of CD8 T cells (Chaput et al, 2007). In humans also Tregs cells have
been found at the site of the primary tumours, including breast
cancer (Liyanage et al, 2002).
In addition to TGFb, we found suggestive evidence that IL-6 may
have contributed to T-cell unresponsiveness as well. Interleukin-6
is a potent regulator of DC differentiation (Park et al, 2004), and is
able to initiate the expression of STAT3 in DC. High levels of
STAT3 can prevent the maturation of DC and subsequent
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Figure 6 Effect of IL-6 on Mage-b-induced immune responses in vitro. To analyse the effect of IL-6 on Mage-b-specific immune responses in vitro, draining
lymph nodes (LNs) of 4T1 tumour-bearing mice were cocultured with or without 64pT tumour cells, expressing highly Mage-b, and producing high levels of
IL-6. These cocultures were performed in the absence or presence of anti-IL-6 antibodies (A). After 2 days of stimulation, the production of IFNg was
determined with quantitative ELISA. In this experiment, the lymph nodes (LNs) of 10 mice were pooled. In addition, spleen cells of 4T1 tumour-bearing mice
were cocultured with or without autologous bone marrow (BM) cells transfected with pcDNA3.1-Mage-b and pCMV-GM-CSF. These cocultures were
performed in the absence or presence of purified IL-6 (B). After 2 days of stimulation, the number of IFNg-producing cells was determined with an ELISPOT
reader. This experiment was performed twice with spleens of mice that received vaccination with LM-LLO-Mage-b/2nd. In each experiment, spleens of five
mice were pooled. Controls such as BM cells transfected with pcDNA3.1-Mage-b and/or pCMV-GM-CSF, or non-transfected BM cells, did not produce
IFNg (data not shown). The results of both assays were subjected to statistical analysis using the unpaired t-test. The error bars represent the s.e.m.
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spresentation of antigens (Xie et al, 2003), resulting in T-cell
inhibition. Both 4T1 primary tumours and metastases secrete IL-6
(Gravekamp et al, 2008). However, the primary tumours are 100–
100000 times larger than the metastases. Therefore, it is expected
that the accumulation of IL-6 is much higher in the environment of
the primary tumours than in the environment of the metastases.
We then hypothesised that the high accumulation of IL-6 may have
downregulated Mage-b-specific immune responses at the site of
the primary tumour. To evaluate this hypothesis, we analysed the
effect of IL-6 on Mage-b-specific immune responses in vitro.
Indeed, IL-6-neutralising antibodies were able to restore Mage-b-
specific immune responses in draining LNs of 4T1 tumour-bearing
mice in vitro when restimulated with Mage-b, whereas purified IL-
6 completely prevented the induction of Mage-b-specific immune
responses in the spleen of 4T1 tumour-bearing mice, when
restimulated with Mage-b. Here, we demonstrated that IL-6
contributed to the inhibition of Mage-b-specific immune re-
sponses in vitro. Whether IL-6 has contributed to T-cell inhibition
at the site of the primary tumour in vivo needs to be further
analysed. High levels of IL-6 have been found in many human
breast cancers (Kuang et al, 1998; Sotiriou et al, 2001). Moreover,
IL-6 promotes tumour growth (Celis et al, 2005) and may induce
chemoresistance (Conze et al, 2001). Therefore, agents that inhibit
the production of IL-6 could improve the efficacy of vaccination or
chemotherapy against breast cancer.
Finally, we have studied safety issues of the LM-LLO-Mage-b/
2nd vaccine. It is known that LM infects kupfer cells and
hepatocytes in the liver, macrophages in the spleen, and epithelial
cells in the gastro intestines (GI) (Vazquez-Boland et al, 2001).
However, the attenuated Listeria bacteria will be cleared by the
immune system within 3–5 days after immunisation. After three
immunisations with LM-LLO-Mage-b/2nd, we found some inflam-
matory spots in the liver, but not in the spleen or GI. Moreover,
LM-LLO-based vaccines have been already tested in cancer
patients in phase I/II clinical trials, and flu-like symptoms are
the only side effects observed (Rothman, 2008).
In summary, we have demonstrated here that vaccination with
LM-LLO-Mage-b/2nd reduced the number of 4T1 metastases
dramatically in correlation with robust Mage-b-specific CD8
T-cell responses in vitro. Unfortunately, no effect was observed
on the primary tumours, and this was correlated with the complete
absence of Mage-b-specific T-cell responses in vitro. Therefore,
our results suggest that vaccination with MAGE-B/2nd may
dramatically improve the clinical outcome of breast cancer
therapy, if applied after removal of the primary tumour.
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